Karl L. Mettinger

Dr. Mettinger has more than 30 years of experience as an executive in the life science industry, and has been involved with the successful development of new therapeutics, including a number of oncology, hematology, cardiovascular and CNS drugs and biologic products approved by regulatory agencies worldwide. Dr. Mettinger is the Principal and Founder of Progressive Clinical partners and helped accelerate and facilitate approvals of a novel oral breakthrough therapy in lymphoma and leukemia, leading to the USD21B market cap and acquisition. He was also a consultant to Philantropist /Investor Edward Bosarge (Capital Technologies, Houston and Tissue Genesis LLC, Honolulu) helping establish a franchise in cellular therapeutics / Regenerative Medicine. He served as Medical Director of Hematology and as Deputy General Manager of the cardiovascular business unit, of bi (Pharmacia, now part of Pfizer), in Sweden, as Medical Director/ Executive Director at IVAX Corporation (acquired by Teva); Chief Medical Officer/Senior Vice President at SuperGen, (Astex, acquired by Otsuka); Chief Medical Officer at Oncolytics Biotech Inc, AB ; co-founder and past President of the Swedish Stroke Society, a 10,000-member stroke research and patient support organization. Dr. Mettinger received his M.D. from the University of Lund in Sweden and his Ph.D. in Hematology/Neurology from, and is a former Associate Professor of, the Karolinska Institutet, the home of the Nobel Prize in Medicine and Physiology in Stockholm.